Chimeric Antigen Receptor News and Research

RSS

New guidelines for identifying and treating high-risk IEC-HS patients

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory disease. However, its clinical success is accompanied by a spectrum of immune-related toxicities, which remain a major challenge in practice.

15 May 2026

Researchers develop pH and redox-sensitive systems to reduce immunotherapy toxicity

Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small subset of patients benefit. Many solid tumors remain "cold," characterized by poor immune cell infiltration and resistance to immune checkpoint blockade (ICB).

15 May 2026

Engineered regulatory T cells offer a path toward immunosuppression-free transplants

Organ transplantation remains the cornerstone treatment for end-stage organ failure. While conventional broad-spectrum immunosuppression effectively controls acute rejection, it fails to address chronic rejection and carries long-term side effects including infection, malignancy, and metabolic disorders.

8 May 2026

Food timing may shape how T cells respond to infection and therapy

Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic capacity, cytokine production, and persistence after activation. The study identifies triglyceride-rich chylomicrons as key drivers of this effect, suggesting nutritional timing may matter for immune monitoring, vaccination research, and cell-therapy manufacturing.

30 Apr 2026

From killers to strategists: CAR T cells enter their multifunctional era

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.

30 Apr 2026

Single-cell sequencing reveals why some CAR-T therapies succeed while others fail

Single-cell RNA sequencing is giving researchers a clearer view of why some CAR-T cells persist, expand, kill tumors effectively, or become exhausted. The review synthesizes 44 clinical scRNA-seq studies involving 500 patients and highlights how exhaustion, memory, cytotoxicity, clonal diversity, and metabolism may shape CAR-T responses.

30 Apr 2026

Metabolic rewiring could help CAR-T cells fight solid tumors

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells inside solid tumors. It highlights metabolic reprogramming as a promising strategy to improve CAR-T cell persistence, adaptability, and anti-tumor function.

29 Apr 2026

Scientists redesign CAR-T cells to fight more than cancer

This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic viral infections, and next-generation immune-cell platforms. It highlights promising engineering advances, including universal CAR-T cells, in vivo delivery, CAR-NK cells, and safety switches, while emphasizing unresolved challenges in durability, safety, scalability, and global access.

29 Apr 2026

Glycocalyx modification boosts immune cell targeting against B lymphoma

A new study published in Engineering provides mechanistic insights into live-cell glycocalyx engineering and supports the rational design of next-generation adoptive cell therapies (ACTs) against B lymphoma, addressing limitations such as high costs and restricted antigen specificity in current treatments.

25 Apr 2026

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

21 Apr 2026

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026

FDA clears investigational new drug application to test sCAR-T therapy for autoimmune conditions

Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions.

10 Apr 2026

Study outlines principles for using CAR immunotherapies to treat neurodegenerative diseases

A UAB research team defines the criteria that CAR immunotherapies for neurodegenerative diseases must meet to advance both conceptually and in trials, which are still at a very preliminary stage, in a review study published in the journal Trends in Pharmacological Sciences.

8 Apr 2026

Lipid nanoparticles help CAR T cells melt pancreatic cancer barriers

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has one of the lowest rates of survival among major malignancies.

31 Mar 2026

Study reveals CAR T approach for hard-to-treat solid tumors

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma.

30 Mar 2026

Implantable device boosts immune cells to fight cancer effectively

Immunotherapy has transformed cancer treatment by harnessing the body's own immune system to fight disease.

17 Mar 2026

New CAR-T cell therapy shows promise for treating osteosarcoma

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has puzzled medical researchers for 40 years.

17 Mar 2026

New CAR-NKT cell therapy shows promise against aggressive endometrial cancer

Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival rates have steadily declined over the last few decades.

16 Mar 2026

Simplified nanoparticles "educate" the immune system to find and destroy disease-causing cells

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can "educate" the immune system to find and destroy disease-causing cells throughout the body.

11 Mar 2026

$Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia$

Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T cells to target specific antigens on leukemia cells, with the goal of identifying and eliminating them.

9 Mar 2026

Chimeric Antigen Receptor News and Research

New guidelines for identifying and treating high-risk IEC-HS patients

Researchers develop pH and redox-sensitive systems to reduce immunotherapy toxicity

Engineered regulatory T cells offer a path toward immunosuppression-free transplants

Food timing may shape how T cells respond to infection and therapy

From killers to strategists: CAR T cells enter their multifunctional era

Single-cell sequencing reveals why some CAR-T therapies succeed while others fail

Metabolic rewiring could help CAR-T cells fight solid tumors

Scientists redesign CAR-T cells to fight more than cancer

Glycocalyx modification boosts immune cell targeting against B lymphoma

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

FDA clears investigational new drug application to test sCAR-T therapy for autoimmune conditions

Study outlines principles for using CAR immunotherapies to treat neurodegenerative diseases

Lipid nanoparticles help CAR T cells melt pancreatic cancer barriers

Study reveals CAR T approach for hard-to-treat solid tumors

Implantable device boosts immune cells to fight cancer effectively

New CAR-T cell therapy shows promise for treating osteosarcoma

New CAR-NKT cell therapy shows promise against aggressive endometrial cancer

Simplified nanoparticles "educate" the immune system to find and destroy disease-causing cells

Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®